Download PDF
Thromb Haemost 1996; 75(04): 529-535
DOI: 10.1055/s-0038-1650315
Review Article
Schattauer GmbH Stuttgart

Elevated Fibrinopeptide A and B Levels during Thrombolytic Therapy: Real or Artefactual?

Jeffrey I Weitz
The Department of Medicine, McMaster University and Hamilton Civic Hospitals Research Centre, Hamilton, Ontario, Canada
› Author Affiliations
Further Information

Publication History

Received 27 June 1994

Accepted after revision 11 January 1996

Publication Date:
10 July 2018 (online)

  PDF Download  Permissions and Reprints

Summary

There is good evidence that thrombolytic therapy induces a procoagulant state that retards the lytic process and triggers reocclusion. Thus, both in experimental animal systems and in humans, potent inhibitors of platelets and antithrombin Ill-independent thrombin inhibitors have been shown to be better than heparin at accelerating thrombolysis and preventing reocclusion. These in vivo observations have lent credence to the concept that elevated FPA levels that are suppressed by heparin reflect systemic activation of coagulation during the thrombolytic process. However, this concept may not be correct. Thus, when heparin is given in conjunction with plasminogen activators only modest increases in FPA levels are found, and our data suggest that this is due, at least in part, to the activity of enzymes other than thrombin. In the absence of concomitant heparin, thrombolytic therapy causes a much greater increase in the FPA values. These high FPA values are rapidly reduced by heparin, even though heparin has limited antithrombotic activity in the setting of pharmacologic thrombolysis. Based on these considerations, we believe that plasma FPA and desarginine FPB levels should not be used as specific markers of thrombin activity during the course of thrombolytic therapy and suppression of elevated FPA values by heparin should not be accepted as evidence that heparin is effective in this clinical setting.

 

  • References

  • 1 Haskel EJ, Prager NA, Sobel BE, Abendschein DR. Relative efficacy of antithrombin compared with antiplatelet agents in accelerating coronary thrombolysis and preventing early reocclusion. Circulation 1991; 83: 1048-1056
    CrossrefPubMedGoogle Scholar
  • 2 Klement P, Borm A, Hirsh J, Wilson G, Maraganore J, Weitz J. The effect of thrombin inhibitors on tissue plasminogen activator-mediated thrombolysis in a rat model. Thromb Haemost 1992; 68: 64-68
    Article in Thieme ConnectPubMedGoogle Scholar
  • 3 Rigel DF, Olson RW, Lappe RW. Comparison of hirudin and heparin as adjuncts to streptokinase thrombolysis in a canine model of coronary thrombosis. Circ Res 1992; 72: 1091-1102
    PubMedGoogle Scholar
  • 4 Lidon R-M, Theroux P, Lesperance J, Adelman B, Bonan R, Duval D, Levesque J. A pilot, early angiographic patency study using a direct thrombin inhibitor as adjunctive therapy to streptokinase in acute myocardial infarction. Circulation 1994; 89: 1567-1572
    CrossrefPubMedGoogle Scholar
  • 5 Theroux P, Perez-Villa F, Waters D, Lesperence J, Shabani F, Bonan R. Randomized double-blind comparison of two doses of hirulog with heparin as adjunctive therapy to streptokinase to promote early patency of the infarct-related artery in acute myocardial infarction. Circulation 1995; 91: 2132-2139
    CrossrefPubMedGoogle Scholar
  • 6 Cannon CP, McCabe CH, Henry TD, Schweiger MJ, Gibson RS, Mueller HS, Becker RC, Kleiman NS, Haugland M, Anderson JL, Sharaf BL, Edwards SJ, Rogers WJ, Williams DO, Braunwald E. A pilot trial of recombinant desulfatohirudin compared with heparin in conjunction with tissue-type plasminogen activator and aspirin for acute myocardial infarction: Results of the thrombolysis in myocardial infarction (TIMI) 5 trial. J Am Coll Cardiol 1994; 23: 993-1003
    CrossrefPubMedGoogle Scholar
  • 7 Eisenberg PR, Sherman LA, Schectman K, Perez J, Sobel BE, Jaffe AS. Fibrinopeptide A: A marker of acute coronary thrombolysis. Circulation 1985; 71: 912-918
    CrossrefPubMedGoogle Scholar
  • 8 Mombelli G, Im Hof V, Haeberli A, Straub PW. Effect of heparin on plasma fibrinopeptide A in patients with acute myocardial infarction. Circulation 1984; 69: 684-689
    CrossrefPubMedGoogle Scholar
  • 9 Eisenberg PR, Sherman LA, Rich M, Schwartz D, Schectman K, Geltman EM, Sobel BE, Jaffe AS. Importance of continued activation of thrombin reflected by fibrinopeptide A to the efficacy of thrombolysis. J Am Coll Cardiol 1986; 7: 1255-1262
    CrossrefPubMedGoogle Scholar
  • 10 Eisenberg PR, Sherman LA, Jaffe AS. Paradoxic elevation of fibrinopeptide A after streptokinase: Evidence of continued thrombosis despite intense fibrinolysis. J Am Coll Cardiol 1987; 10: 527-529
    CrossrefPubMedGoogle Scholar
  • 11 Seitz R, Blanke H, Pratorius G, Eckhard Strauer B, Egbring R. Increased thrombin activity during thrombolysis. Thromb Haemost 1988; 59: 541-542
    Article in Thieme ConnectPubMedGoogle Scholar
  • 12 Rapold HJ, Kuemmerli J, Weiss M, Baur H, Haeberli A. Monitoring of fibrin generation during thrombolytic therapy of acute myocardial infarction with recombinant tissue-type plasminogen activator. Circulation 1989; 79: 980-989
    CrossrefPubMedGoogle Scholar
  • 13 Rapold HJ. Promotion of thrombin activity by thrombolytic therapy without simultaneous anticoagulation. Lancet 1990; 1: 481
    PubMedGoogle Scholar
  • 14 Rapold HJ, Grimaudo V, Declerck PJ, Kruithof EKO, Bachmann F. Plasma levels of plasminogen activator inhibitor type 1, (3-thromboglobulin, and fibrinopeptide A before, during, and after treatment of acute myocardial infarction with alteplase. Blood 1991; 78: 1490-1495
    PubMedGoogle Scholar
  • 15 Owen J, Friedman KD, Grossmann BA, Wilkins C, Berke AD, Powers ER. Thrombolytic therapy with tissue-type plasminogen activator or streptokinase induces transient thrombin activity. Blood 1988; 72: 616-620
    PubMedGoogle Scholar
  • 16 Rapold HJ, de Bono D, Arnold AER, Amout J, De Cock F, Collen D, Verstraete M. Plasma fibrinopeptide A levels in patients with acute myocardial infarction treated with alteplase. Circulation 1992; 85: 928-934
    CrossrefPubMedGoogle Scholar
  • 17 Galvani M, Abendschein DR, Ferrini D, Ottani F, Rusticali F, Eisenberg PR. Failure of fixed dose intravenous heparin to suppress increases in thrombin activity after coronary thrombolysis with streptokinase. J Am Coll Cardiol 1994; 24: 1445-1452
    CrossrefPubMedGoogle Scholar
  • 18 Merlini PA, Bauer KA, Oltrona L, Ardissino D, Spinola A, Cattaneo M, Broccolino M, Mannucci PM, Rosenberg RD. Thrombin generation and activity during thrombolysis and concomitant heparin therapy in patients with acute myocardial infarction. J Am Coll Cardiol 1995; 25: 203-209
    CrossrefPubMedGoogle Scholar
  • 19 Topol EJ, George BS, Keretakes DJ, Stump DC, Candela RJ, Abbottsmith CW, Aronson L, Pickel A, Boswick JM, Lee KL, Ellis SG, Califf RM. and the TAMI Study Group. A randomized controlled trial of intravenous tissue plasminogen activator and early intravenous heparin in acute myocardial infarction. Circulation 1989; 79: 281-286
    CrossrefPubMedGoogle Scholar
  • 20 Mirshahi M, Soria J, Soria C, Faivre F, Lu H, Courtney M, Roitsch C, Tripier D, Caen JP. Evaluation of the inhibition by heparin and hirudin of coagulation activation during rt-PA-induced thrombolysis. Blood 1989; 74: 1026-1030
    PubMedGoogle Scholar
  • 21 Hogg PJ, Jackson CM. Fibrin monomer protects thrombin from inactivation by heparin-antithrombin III: implications for heparin efficacy. Proc Natl AcadSci USA 1989; 86: 3619-3623
    CrossrefPubMedGoogle Scholar
  • 22 Weitz JI, Hudoba M, Massel D, Maraganore J, Hirsh J. Clot-bound thrombin is protected from inhibition by heparin-antithrombin III but is susceptible to inactivation by antithrombin Ill-independent inhibitors. J Clin Invest 1990; 86: 385-391
    CrossrefPubMedGoogle Scholar
  • 23 Schaffer LW, Davidson JT, Vlasuk GP, Siegel PKS. Antithrombotic efficacy of recombinant tick anticoagulant peptide. A potent inhibitor of coagulation factor Xa in a primate model of arterial thrombosis. Circulation 1991 84. 1741-1748
    PubMedGoogle Scholar
  • 24 Weitz JI, Cruickshank MK, Thong B, Leslie B, Levine MN, Ginsberg J, Eckhardt T. Human tissue-type plasminogen activator releases fibrino-peptides A and B from fibrinogen. J Clin Invest 1988; 82: 1700-1707
    CrossrefPubMedGoogle Scholar
  • 25 Takagi T, Doolittle RF. Amino acid sequence studies on plasmin-derived fragments of human fibrinogen: Amino-terminal sequences of intermediate and terminal fragments. Biochemistry 1975; 14: 940-946
    CrossrefPubMedGoogle Scholar
  • 26 Weitz JI, Leslie B. Urokinase has direct catalytic activity against fibrinogen and renders it less clottable by thrombin. J Clin Invest 1990; 86: 203-212
    CrossrefPubMedGoogle Scholar
  • 27 Kumar R, Beguin S, Hemker HC. The effect of fibrin clots and clot-bound thrombin on the development of platelet procoagulant activity. Thromb Haemost 1995; 74: 962-968
    Article in Thieme ConnectPubMedGoogle Scholar
  • 28 Kumar R, Beguin S, Hemker HC. The influence of fibrinogen and fibrin on thrombin generation - evidence for feedback activation of the clotting system by clot bound thrombin. Thromb Haemost 1994; 72: 713-721
    Article in Thieme ConnectPubMedGoogle Scholar
  • 29 Prins M, Weitz JI. Heparin inhibits the amplification of coagulation mediated by clot-bound thrombin. Thromb Haemost 1991 65. 759 (Abstract).
    PubMedGoogle Scholar
  • 30 Lee CD, Mann KG. The activation of human factor V by plasmin. Blood 1989; 73: 185-190
    PubMedGoogle Scholar
  • 31 Kaplan AP, Austen KF. prealbumin activator of prekallikrein II. Derivation of activators of prekallikrein from active Hageman factor by digestion with plasmin. J Exp Med 1971; 133: 696-712
    CrossrefPubMedGoogle Scholar
  • 32 Eisenberg PR, Miletich JP, Sobel BE. Factors responsible for the differential procoagulant effects of diverse plasminogen activators in plasma. Fibrinolysis 1991; 5: 217-224
    PubMedGoogle Scholar
  • 33 Ewald GA, Eisenberg PR. Plasmin-mediated activation of contact system in response to pharmacological thrombolysis. Circulation 1995; 91: 28-36
    CrossrefPubMedGoogle Scholar
  • 34 Nichols AB, Owen J, Grossman BA, Marcella JJ, Fleisher LN, Lee MM. Effect of heparin bonding on catheter-induced fibrin formation and platelet activation. Circulation 1984; 70: 843-848
    CrossrefPubMedGoogle Scholar
  • 35 Francis CW, Markham RE, Barlow GH, Florack TM, Dobrzynski DM, Marder VJ. Thrombin activity of fibrin thrombi and soluble plasmic derivatives. J Lab Clin Med 1983; 102: 220-203
    PubMedGoogle Scholar
  • 36 Weitz JI, Leslie B, Hudoba M. Thrombin remains bound to soluble fibrin degradation products and is partially protected from inhibition by heparin-antithrombin III. Thromb Haemost 1991 65. 931 (Abstract).
    PubMedGoogle Scholar
  • 37 Bar-Shavit R, Eldor A, Vlodavsky I. Binding of thrombin to subendothelial extracellular matrix: protection and expression of functional properties. J Clin Invest 1989; 84: 1096-1104
    CrossrefPubMedGoogle Scholar
  • 38 Levine MN, Weitz J, Turpie AGG, Andrew M, Cruickshank M, Hirsh J. A new short infusion dosage regimen of recombinant tissue plasminogen activator in patients with venous thromboembolic disease. Chest 1990; 97: 168-171
    CrossrefPubMedGoogle Scholar
  • 39 Levine MN, Hirsh J, Weitz J, Cruickshank M, Neemeh J, Turpie AGG, Gent M. A randomized trial of a single bolus dosage regimen of recombinant tissue plasminogen activator in patients with acute pulmonary embolism. Chest 1990; 98: 1473-1479
    CrossrefPubMedGoogle Scholar
  • 40 Bilizekian SB, Nossel HL, Butler Jr. VP. Canfield RE. Radioimmunoassay of fibrinopeptide B and kinetics of fibrinopeptide cleavage by different enzymes. J Clin Invest 1975; 56: 438-445
    CrossrefPubMedGoogle Scholar
  • 41 Nossel HL, Yudelman I, Canfield RE, Butler Jr VP, Spanondis KS, Wilner GD, Qureshi GD. Measurement of fibrinopeptide A in human blood. J Clin Invest 1974; 54: 43-53
    CrossrefPubMedGoogle Scholar
  • 42 Eckhardt T, Nossel HL, Hurlet-Jensen A, LaGamma KS, Owen J, Auerbach M. Measurement of desarginine fibrinopeptide B in human blood. J Clin Invest 1981; 67: 809-816
    CrossrefPubMedGoogle Scholar
  • 43 Verstraete M, Bory M, Collen D, Erbel R, Lennane RJ, Mathey DG, Michels HR, Schartl M, Uebis R, Bernard R, Brower RW, de Bono DP, Huhmann W, Lubsen J, Meyer J, Rutsch W, Schmidt W, von Essen R. Randomized trial of intravenous recombinant tissue-type plasminogen activator versus intravenous streptokinase in acute myocardial infarction. Lancet 1985; i: 842-847
    PubMedGoogle Scholar
  • 44 Hajjar KA, Jacovina AT, Chacko J. An endothelial cell receptor for plasminogen/tissue plasminogen activator. J Biol Chem 1995; 269: 21191-21197
    PubMedGoogle Scholar
  • 45 Cesarman GM, Guevara CA, Hajjar KA. An endothelial cell receptor for plasminogen/tissue plasminogen activator (t-PA). J Biol Chem 1994; 269: 21198-21203
    PubMedGoogle Scholar
  • 46 Eisenberg PR, Miletich JP. Induction of marked thrombin activity by pharmacologic concentrations of plasminogen activators in nonanticoagulated whole blood. Thromb Res 1989; 55: 635-643
    CrossrefPubMedGoogle Scholar
  • 47 Eisenberg PR, Miletich JP, Sobel BE, Jaffe AS. Differential effects of activation of prothrombin by streptokinase compared with urokinase and tissue-type plasminogen activator (t-PA). Thromb Res 1988; 50: 707-17
    CrossrefPubMedGoogle Scholar
  • 48 Eisenberg PR, Miletich JP. Proteolysis of prothrombin with pharmacologic plasminogen activation. Circulation 1989 80. 317 (abstr.)
    PubMedGoogle Scholar
  • 49 Seitz R, Pelzer H, Immel A, Egbring R. Prothrombin activation by thrombolytic agents. Fibrinolysis 1993; 7: 109-115
    PubMedGoogle Scholar
  • 50 Gjonnaess H. Cold promoted activation of factor VII. V. Relation to the fibrinolytic system. Thrombos Diathes Haemorrh 1973; 29: 143-153
    PubMedGoogle Scholar
  • 51 Laake K, Østerud B. Activation of purified factor VII by human plasmin, plasma kallikrein, and activated components of the human intrinsic blood coagulation system. Thromb Res 1975; 5: 759-772
    PubMedGoogle Scholar
  • 52 Brommer EJP, Meijer P. Thrombin generation induced by the intrinsic or extrinsic coagulation pathway is accelerated by streptokinase, independently of plasminogen. Thromb Haemost 1993; 70 (06) 995-997
    Article in Thieme ConnectPubMedGoogle Scholar
  • 53 Canfield RE, Dean J, Nossel HL, Butler Jr. VP. Reactivity of fibrinogen and fibrinopeptide A containing fragments with antisera to fibrinopeptide A. Biochemistry 1976; 15: 1203-1209
    CrossrefPubMedGoogle Scholar
  • 54 Weitz JI, Landman SL, Crowley KA, Birken S, Morgan FJ. Development of an assay for in vivo human neutrophil elastase activity. Increased elastase activity in patients with a,-proteinase inhibitor deficiency. J Clin Invest 1986; 78: 155-162
    CrossrefPubMedGoogle Scholar
  • 55 Kudryk B, Gidlund M, Rohoza A, Ahadi M, Coiffe D, Weitz JI. Use of a synthetic homologue of human fibrinopeptide A for production of a monoclonal antibody specific for the free peptide. Blood 1989; 74: 1036-1044
    PubMedGoogle Scholar
  • 56 Koehn JA, Canfield RE. Purification of human fibrinopeptides by high-performance liquid chromatography. Analytical Biochemistry 1981; 116: 349-356
    CrossrefPubMedGoogle Scholar
  • 57 Leeksma OC, Meijer-Huizinga F, Stoeman-van Dalen EA, van Ginkel CJW, van Aken WG, van Mourik JA. Fibrinopeptide A and the phosphate content of fibrinogen in venous thromboembolism and disseminated intra-vascular coagulation. Blood 1986; 67: 1460-1467
    PubMedGoogle Scholar
  • 58 Liu CY, Sobel JH, Weitz JI, Kaplan KL, Nossel HL. Immunologic identification of the cleavage products from the AΑ- and BΒ-chains in the early stages of plasmin digestion of fibrinogen. Thromb Haemost 1986; 56: 100-106
    Article in Thieme ConnectPubMedGoogle Scholar
  • 59 Wun TC, Ossowski L, Reich E. A proenzyme form of urokinase. J Biol Chem 1982; 257: 7262-7628
    PubMedGoogle Scholar
  • 60 Peterson LC, Lund LR, Nielsen LS, Dano K, Skriver L. One-chain urokinase-type plasminogen activator from human sarcoma cells is a proenzyme with little or no intrinsic activity. J Biol Chem 1988; 263: 11189-11195
    PubMedGoogle Scholar